 2. An increase of greater than 15 and 200ml in FEV1 with asthma treatment over the last 3 years if there is no record of such improvement, participants will be evaluated via spirometry pre- and post-bronchodilator at the first study visit. An increase in FEV1 or FVC greater than 12 and 200 ml in FEV1 30 minutes following albuterol administration will represent evidence of reversible airflow obstruction. If a spirometer is not immediately available, participants may be evaluated using a peak flow meter, which reports a PEF. A PEFpp less than 80 and an improvement of at least 60 L per minute after the administration of albuterol will represent evidence of reversible airflow obstruction 